Research Fellow. 1.5 Senior Research Fellow 2 The criteria for appointment shall be as follows:
Research Fellow. 2.4.1 An earned master’s degree from an accredited institution and a minimum of eight
Research Fellow Sample Clauses
Related to Research Fellow
Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.
Research Funding In consideration for the performance of the Screening Program and activities related thereto by NeoGenesis, Schering shall pay to NeoGenesis research funding during the term of the Screening Program at the rate of [*] term of the Screening Program. Such payments constitute [*]payment for FTEs at a rate of [*] per year per FTE, with [*] of such funding to be paid by Schering-Plough Ltd. under the terms of the International Agreement. The amount of such funding shall be based upon the actual number of FTEs assigned by NeoGenesis to work on the Screening Program pursuant to Section 2.2(f), it being understood that except as otherwise agreed by the parties in writing, research funding shall be paid based upon [*] FTEs. Research funding shall be payable in equal quarterly installments during the term of the Screening Program, with the first such payment due within [*] after the Effective Date and each successive payment due quarterly in advance on the first day of each calendar quarter starting on October 1, 2001. It is understood and agreed by the parties that first two research funding payments due under this Agreement [*] represents payment for work performed by NeoGenesis in connection with the Screening Program during the entire 2001 calendar year, including activities performed during the period extending from January 1, 2001 until the Effective Date. In the event that the term of the Screening Program is extended, the FTE rate payable under this Section 4.1 in each such extension year shall be increased by the CPI (as defined below). If Schering is unwilling to provide funding for such documented cost increases and the parties are unable to resolve such funding matter to their mutual satisfaction within forty-five (45) days then the Screening Program shall not be extended for such extension year. If in any * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
Research Support opioid abatement research that may include, but is not limited to, the following:
University Any notice may be served upon the University by delivering it, in writing, to the University at the address set forth on the last page of this Agreement, by depositing it in a United States Postal Service deposit box with the postage fully prepaid and with the notice addressed to the University at the aforementioned address, or by sending a facsimile of it to the University facsimile number set forth on the last page of this Agreement.
Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.
Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be conducted by the Principal Investigator at the University.
Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.
